Press Release

Anti-Fungal Drugs Market to Grow with a CAGR of 4.33% through 2030

Increasing number of antifungal drugs as over the counter and rising consumption of antifungal drugs in developing regions is expected to drive the Global Anti-Fungal Drugs Market growth in the forecast period, 2026-2030.

 

According to TechSci Research report, “Anti-Fungal Drugs Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the Global Anti-Fungal Drugs Market stood at USD 12.47 billion in 2024 and is anticipated to grow with a CAGR of 4.33% in the forecast period, 2026-2030. The antifungal drugs market is witnessing significant expansion due to the growing prevalence of various fungal infections, including fungal nail infections, ringworm, and more.

Moreover, the increasing demand for antifungal drugs as over the counter (OTC) medications, the rising demand for generic antifungal drugs, the escalating incidence of nosocomial infections worldwide, and the continuous drug innovations such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, among others, will contribute to the surge in antifungal drug demand.

           

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Anti-Fungal Drugs Market

 

Market drivers, such as the increasing prevalence of fungal infections, present significant growth opportunities for vendors. However, market participants will face challenges due to factors like the rise of multidrug-resistant fungal pathogens. To capitalize on these opportunities, market vendors should prioritize growth prospects in fast-growing segments while maintaining their positions in slow-growing segments.

Driving demand in the global antifungal drugs market is the growing awareness of fungal infections and the rising instances of such infections due to unhygienic environments in densely populated cities. The most prevalent systemic fungal infection, systemic candidiasis, is expected to drive growth in the coming years. The availability of various antifungal drugs and the popularity of over-the-counter antifungal drugs for dermal infections have positively impacted the market. Antifungal drugs play a crucial role in inhibiting fungal cell wall development, disrupting cell membranes, and preventing cell proliferation. The market for antifungal therapies includes powders, drugs, pastes, and ointments. Azoles antifungal drugs currently hold a dominant share in the market, driven by increasing awareness.

Additionally, the rising demand for antifungal powder contributes to the market's revenue growth. Antifungal powder not only cures fungal infections but also reduces itching, inhibits recurrence, and provides relaxing maintenance therapy. These drugs help prevent and treat fungal skin infections caused by sweat and moisture. Therefore, powder-form drugs are used to treat itching, irritation, rashes, and swelling in various body parts containing Clotrimazole, which effectively destroys fungi and drives revenue growth. In May 2022, Bayer's Consumer Health division launched the new and improved Canesten anti-fungal treatment solution in India, available in powder and cream forms. These products possess anti-fungal characteristics that aid in the prevention and treatment of skin infections.

Other factors contributing to market growth include favorable government initiatives, corporate funds, and growing healthcare budgets in developing economies. Technological advancements in diagnostic tests and devices have also contributed to more accurate treatment, further fueling market growth. However, the continued preference for conventional drugs and the high cost and side effects of antifungal drugs poses challenges to their swift adoption. Additionally, the diminishing efficacy of drugs due to increasing fungal resistance is another market challenge to address.

 

The Global Anti-Fungal Drugs Market is segmented into drug class, indication, infection type, route of administration, end user, distribution channel, regional distribution, and company.

 The Echinocandins segment is anticipated to be the second most dominant drug class during the forecast period due to several key factors. Echinocandins, including drugs like caspofungin, micafungin, and anidulafungin, are highly effective against a wide range of fungal infections, particularly Candida and Aspergillus species. They offer a favorable safety profile and are generally well-tolerated, making them a preferred option, especially in immunocompromised patients. Their fungicidal activity against Candida species and fungistatic action against Aspergillus contribute to their increasing clinical use. Moreover, the rising incidence of invasive fungal infections and growing resistance to older antifungal agents like azoles have further boosted demand. Echinocandins are often used in hospital settings, especially in intensive care units, which enhances their market share. Continued R&D efforts and expanding indications for use also support growth in this segment, reinforcing its strong position in the antifungal therapeutics market.

Europe is projected to be the fastest-growing region in the antifungal drugs market during the forecast period, driven by several key factors. The increasing prevalence of fungal infections, especially among aging populations and immunocompromised individuals, such as cancer patients and organ transplant recipients, is a major growth driver. Rising awareness among healthcare providers and patients regarding early diagnosis and treatment of fungal infections has led to greater adoption of antifungal therapies across the region.

Furthermore, the European healthcare infrastructure is well-developed, with robust public and private healthcare systems that support the availability and accessibility of advanced antifungal treatments. Governments and healthcare agencies in countries such as Germany, France, and the UK are investing in improving infection control and hospital hygiene, which indirectly supports the demand for effective antifungal agents.

In addition, the European region has a strong pharmaceutical and biotechnology presence, encouraging continuous research and development of new antifungal drugs. Regulatory bodies such as the European Medicines Agency (EMA) provide structured pathways for drug approvals, further facilitating market growth. Collaborations between academia, hospitals, and pharmaceutical companies are also fostering innovation. Combined with rising antimicrobial resistance and the emergence of new fungal pathogens, these factors position Europe as the fastest-growing market in the antifungal drugs landscape.

Major companies operating in Global Anti-Fungal Drugs Market are:

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • GSK plc
  • Glenmark Pharmaceuticals Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Apex Laboratories Pvt. Ltd.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

“The increasing prevalence of fungal and nosocomial infections is a key factor that contributes to a positive market outlook. Antifungal drugs demonstrate efficacy against both systemic and superficial infections acquired from exposure to contaminated surfaces in hospitals or humid conditions. Furthermore, the convenient availability of over the counter (OTC) drugs in urban and rural areas propels market growth. As health consciousness rises among the masses, consumers increasingly choose OTC therapeutics for timely treatment of minor infections. Moreover, product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for invasive fungal infection treatment, serve as growth-inducing factors. Pharmaceutical manufacturers invest extensively in research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets, and injections with enhanced efficacy. Additionally, significant growth in the pharmaceutical industry, coupled with favorable government policies promoting public health, is anticipated to drive market growth.,” said Mr. Karan Chechi, Research Director, TechSci Research, a research-based management consulting firm.


Anti-Fungal Drugs Market Segmented By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Others), By End User (Homecare, Hospitals, Clinics, Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region and Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of Global Anti-Fungal Drugs Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Anti-Fungal Drugs Market.

 

Contact:

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com

Relevant News